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Following the question how to increase the positive detection rate they suggest that nested PCR increases the sample size by a factor of two. However, it is clear that a positive nested PCR result can only be achieved if at least a single target molecule is present within the first round reaction tube. Repeating the test in terms of the additional cycles in nested PCR contributes to the increased sensitivity of nested vs single PCR as end point measurements.
In contrast and as we have stated before, 2 real-time PCR uses a very different system to define and control the detection level, thus precluding any additional benefit of higher cycling under optimized conditions. Highest accuracy with a limited number of replicates is the aim for both strategies, taqman and nested PCR. However, quantitative accuracy should be distinguished from a qualitative scoring term like 'sensitivity' as it depends on the defined cutoff level. We asked whether the Poisson distribution can be imitated experimentally and if so, the lack of deviations from Poisson serves as a marker for quantitative accuracy at very low copy numbers. For this purpose, we performed the experiments in eight-fold replication to obtain reproducible results. To illustrate the underlying logic: it can be reasoned that a less sensitive method would not have been able to reproducibly detect the templates that were present according to Poisson. If, for instance, the expected distribution was 0, 0, 0, 1, 1, 1, 2, 3 (expected value 1), a less sensitive method might have detected 0, 0, 0, 0, 0, 1, 2, 3 and a less precise method might have resulted in 0, 0, 0, 2, 2, 2, 4, 6. In our experiments, real-time PCR showed neither of these aberrations. With respect to practical terms, it was never intended to recommend the routine use of eight replicates in a diagnostic setting.
Without disregarding the importance of the data presented by Guo et al 3 and their preference to competitive nested PCR, recent publications in this journal underscore the potential of quantitive real-time PCR and the need to optimize this strategy. Since MDS in children differs from those seen in adults clinically and biologically, and approximately 40% of the pediatric MDS cases cannot be classified by adult classifications such as the French-American-British classification; the author correctly emphasizes the need for a clear and useful classification for these disorders in childhood. However, the new classification did not differentiate between pediatric MDS and pediatric myeloproliferative syndromes (MPSs). This is a great challenge since some of these chronic myeloid disorders are myeloproliferative rather than myelodysplastic.
For example, the first category of the proposed classification system includes the bridging disorders between MDS and MPS, and JMML is the first in this category. It is true that JMML is included as an MDS/MPS disorder in the WHO classification. However, most of the members of the WHO clinical advisory committee favored including JMML in the MPS category.
2 From a clinical point of view, JMML behaves as MPS. Furthermore, it has the most aggressive proliferation properties in clonogenic assays than any other known disorder. We strongly recommend including JMML as MPS. Similarly, transient myeloproliferative disorder of Down's syndrome is a borderline disorder between MPS and acute leukemia rather than MDS. Therefore, it should not be included in an MDS classification.
